Difference between revisions of "Interferon alfa-2a (Roferon-A)"
Warner-admin (talk | contribs) m |
m |
||
| Line 25: | Line 25: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
| − | [[Category: | + | [[Category:Interferons]] |
[[Category:Chronic myelogenous leukemia medications]] | [[Category:Chronic myelogenous leukemia medications]] | ||
Revision as of 18:41, 27 May 2018
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic myelogenous leukemia
- Follicular lymphoma
- Melanoma
- Neuroendocrine tumors
- Renal cancer
- Squamous cell carcinoma (SCC)
Patient drug information
History of changes in FDA indication
- 6/4/1986: Initial FDA approval